COMT Val158Met polymorphism and breast cancer risk: evidence from 26 case-control studies

Breast Cancer Research and Treatment
Haixia DingZhanwei Wang

Abstract

The Catechol-O-methyltransferase (COMT) plays an important role in the development of breast cancer. Many previous epidemiologic studies explored the association of COMT Val158Met polymorphism with breast cancer susceptibility. However, the results were inconsistent. We therefore performed a meta-analysis of 26 published studies including 16,693 breast cancer patients and 18,261 healthy controls. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association of the COMT Val158Met polymorphism with breast cancer risk. No significant association was found in all genetic models in overall, Asian, European populations. After the studies whose genotype frequencies in the controls did not fulfill Hardy-Weinberg equilibrium were excluded, we found a borderline significant decreased breast cancer risk among Europeans (for the recessive model LL versus HH/HL: OR = 0.90, 95% CI = 0.90-1.00, P (heterogeneity) = 0.33). There was no between-study heterogeneity. In conclusion, COMT Val158Met polymorphism may be a low-penetrant risk factor for breast cancer development in European population.

References

Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Nov 15, 1995·Journal of the National Cancer Institute·M P MadiganR N Hoover
Nov 1, 1996·Carcinogenesis·H S Feigelson, B E Henderson
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Feb 12, 1998·Annals of Internal Medicine·J LauC H Schmid
Dec 17, 1998·Carcinogenesis·R C MillikanD A Bell
Sep 15, 2001·British Journal of Cancer·M Bergman-Jungeström, S Wingren
Nov 15, 2001·International Journal of Clinical Oncology·N HamajimaY Obata
Aug 16, 2002·American Journal of Epidemiology·Julian LittleClarice Weinberg
Apr 25, 2003·Cancer·David E ComingsJames P MacMurray
May 3, 2003·Carcinogenesis·Sara WedrénCecilia Magnusson
Apr 28, 2004·Breast Cancer Research and Treatment·Habibul AhsanRegina M Santella
Jun 17, 2004·Journal of the National Cancer Institute·Alison M DunningBruce A J Ponder
Mar 1, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Wanqing WenWei Zheng
Apr 6, 2006·Breast Cancer Research and Treatment·Mia M GaudetMarilie D Gammon
May 5, 2006·BMC Cancer·Venüs Ummiye OnayHilmi Ozcelik
Mar 28, 2007·Journal of Clinical Laboratory Analysis·Elif Akisik, Nejat Dalay
Mar 15, 2008·Breast Cancer Research and Treatment·Chunyan HeJiali Han
May 6, 2009·International Journal of Cancer. Journal International Du Cancer·Suleeporn SangrajrangTeruhiko Yoshida
May 9, 2009·Breast Cancer Research and Treatment·UNKNOWN MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk

❮ Previous
Next ❯

Citations

Jan 12, 2011·Breast Cancer Research and Treatment·Bo XiWeina Liu
Jun 21, 2013·International Journal of Circumpolar Health·Mandana GhisariEva C Bonefeld-Jørgensen
Mar 19, 2014·Environmental Health : a Global Access Science Source·Mandana GhisariEva C Bonefeld-Jørgensen
Sep 8, 2011·Breast Cancer Research and Treatment·César Fernández-de-las-PeñasManuel Arroyo-Morales
Jun 5, 2013·Drug Discovery Today. Disease Mechanisms·James D Yager
Oct 7, 2011·The Breast : Official Journal of the European Society of Mastology·César Fernández-de-Las-PeñasManuel Arroyo-Morales
Sep 29, 2018·Global Health, Epidemiology and Genomics·A AbbadF Radouani
May 1, 2018·Comprehensive Reviews in Food Science and Food Safety·A Filipa AlmeidaCláudia N Santos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.